Journal of Ocular Pharmacology and Therapeutics · 2007 · 24 citations · 24 references
MedicineOphthalmologyPharmacotherapyOcular Drug DeliveryOcular PharmacologyOphthalmic Drug DeliveryDiabetic RetinopathyOcular PharmacodynamicsOcular Targeted DeliveryRetinal PharmacotherapyRetinal Vascular DiseaseTopical Ophthalmic MedicationsBlood-retinal Barrier PermeabilityNeovascularizationNeovascularization RegressionRetinal Angiogenesis InhibitionRetinal Blood Flow AlterationsRetinal Microvascular ChangesRetinal PharmacologyVascular Targeting
PURPOSE: Combretastatin A-4 (CA-4) is a vascular targeting agent known to rapidly shut off blood flow in new vessels and, as a result, regress neovascularization. In this pilot study, the ability of CA-4 to modify retinal neovascularization, which results in altered retinal vessel blood flow and retinal permeability, was evaluated in aphakic long-term galactose-fed beagles, an animal model that develops diabetes-like retinal neovascularization. METHODS: Two (2) groups of aphakic dogs, each group comprised of 4 galactose-fed dogs and 2 age-matched controls dogs, were utilized. Each group initially received the combretastatin A-4-phosphate prodrug (CA-4P) as either sub-Tenon's injections, administered at the corneoscleral junction, or intravitreal injections. Six (6) weeks after this treatment, all dogs also received systemic (intravenous) injections of CA-4P. Retinal vascular changes were monitored at 2-week intervals by fluorescein angiography. RESULTS: All galactose-fed dogs demonstrated the presence of retinal neovascular lesions by fluorescein angiograms. Fluorescein leakage or perfusion through neovascular vessels was not altered by either sub-Tenon's, intravitreal, or systemic CA-4P administration. Whereas CA-4P was well tolerated by the healthy eyes of the control animals, its administration to some galactose-fed dogs was associated with corneal edema and increases in intraocular pressure following sub-Tenon's and intraocular injections. CONCLUSIONS: Neovascularization in the galactose-fed dog progresses over a period of years, similar to that observed with clinical diabetic retinopathy. The failure of CA-4P to ameliorate neovascularization suggests that chronic, long-term administration may be required to destroy the slowly growing retinal endothelial cells.
24
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
G. Dark, S A Hill, Vivien E. Prise et al. · PubMed · 1997 · 624 citations
Medicine, Oncology, Pharmacology +13
Afshin Dowlati, Kelly M. Robertson, Matthew M. Cooney et al. · PubMed · 2002 · 406 citations
Medicine, Oncology, Pharmacology +17
G. M. Tozer, Vivien E. Prise, John Wilson et al. · PubMed · 1999 · 324 citations
Medicine, Oncology, Pharmacology +17
James Stevenson, Mark Rosen, Weijing Sun et al. · Journal of Clinical Oncology · 2003 · 293 citations
Medicine, Oncology, Pharmacology +17